AU2013240340B2 - PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic - Google Patents

PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic Download PDF

Info

Publication number
AU2013240340B2
AU2013240340B2 AU2013240340A AU2013240340A AU2013240340B2 AU 2013240340 B2 AU2013240340 B2 AU 2013240340B2 AU 2013240340 A AU2013240340 A AU 2013240340A AU 2013240340 A AU2013240340 A AU 2013240340A AU 2013240340 B2 AU2013240340 B2 AU 2013240340B2
Authority
AU
Australia
Prior art keywords
cancers
cancer
pfk
quinolin
prop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013240340A
Other languages
English (en)
Other versions
AU2013240340A1 (en
Inventor
Pooran Chand
Gilles H. Tapolsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Cancer Therapeutics LLC
Original Assignee
Advanced Cancer Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cancer Therapeutics LLC filed Critical Advanced Cancer Therapeutics LLC
Publication of AU2013240340A1 publication Critical patent/AU2013240340A1/en
Application granted granted Critical
Publication of AU2013240340B2 publication Critical patent/AU2013240340B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013240340A 2012-03-29 2013-03-14 PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic Ceased AU2013240340B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261617073P 2012-03-29 2012-03-29
US61/617,073 2012-03-29
PCT/US2013/031159 WO2013148228A1 (en) 2012-03-29 2013-03-14 Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic

Publications (2)

Publication Number Publication Date
AU2013240340A1 AU2013240340A1 (en) 2014-10-23
AU2013240340B2 true AU2013240340B2 (en) 2016-11-10

Family

ID=49261041

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013240340A Ceased AU2013240340B2 (en) 2012-03-29 2013-03-14 PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic

Country Status (9)

Country Link
US (2) US9649305B2 (enExample)
EP (1) EP2831047B1 (enExample)
JP (1) JP6075903B2 (enExample)
CN (2) CN106074368B (enExample)
AU (1) AU2013240340B2 (enExample)
CA (1) CA2868787A1 (enExample)
ES (1) ES2629932T3 (enExample)
IN (1) IN2014DN08886A (enExample)
WO (1) WO2013148228A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CN107635986A (zh) * 2015-05-13 2018-01-26 赛尔维他股份公司 取代的喹喔啉衍生物
US20180147198A1 (en) * 2015-05-28 2018-05-31 University Of Louisville Research Foundation, Inc. Combinations of pfkfb3 inhibitors and immune checkpoint inhibitors to treat cancer
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
CN109890809A (zh) * 2016-11-08 2019-06-14 默克专利股份公司 作为pfkfb的抑制剂的取代的喹喔啉衍生物
CN109136206B (zh) * 2017-06-15 2021-07-23 厦门大学 Pfkfb3蛋白的第194位酪氨酸的磷酸化及其应用
CN109134434B (zh) * 2017-11-06 2021-02-19 北京大学深圳研究生院 喹啉或喹唑啉类化合物及其制备方法和应用
MY209483A (en) * 2019-08-06 2025-07-11 Univ North Carolina Chapel Hill Rna-targeting ligands, compositions thereof, and methods of making and using the same
CN111228265A (zh) * 2020-02-10 2020-06-05 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） p38γ抑制剂在制备治疗胰腺癌药物中的应用
KR102344676B1 (ko) 2020-02-12 2021-12-30 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 근적외선 형광 탐침자로서 유효한 신규 화합물 및 이의 제조방법
CN111996247B (zh) * 2020-08-27 2021-09-10 北京大学人民医院 糖酵解抑制剂及其在修复内皮细胞损伤中的应用
CN114617884B (zh) * 2020-12-10 2023-06-02 中国科学院大连化学物理研究所 Pfk-158在制备抗冠状病毒药物中的应用及药物
JP2024519056A (ja) * 2021-05-16 2024-05-08 メタノイア バイオ インコーポレイテッド 膵疾患及び肝疾患を治療するための方法及び組成物
JP2025505975A (ja) * 2022-01-31 2025-03-05 ニュー フロンティア バイオ インコーポレイテッド ニコチネート及びニコチンアミドリボシドベースの化合物及びその誘導体
CN120695195A (zh) * 2025-06-20 2025-09-26 华中科技大学同济医学院附属协和医院 靶向cdc20和糖酵解通路双靶点抑制剂在治疗子宫内膜癌中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074884A1 (en) * 2007-06-18 2009-03-19 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CN1182846C (zh) * 2003-03-14 2005-01-05 南开大学 水溶性抗癌药紫杉醇复合物及其制备方法
CN1554336A (zh) * 2003-12-23 2004-12-15 广州国桥医药研究有限公司 水溶性青蒿素制剂的制备方法
JP4790704B2 (ja) * 2004-04-12 2011-10-12 トレント・ファーマシューティカルズ・リミテッド Ｈｓｐ７０誘発因子としての２−プロペン−１−オン
CN101020060A (zh) * 2007-03-10 2007-08-22 杨喜鸿 恩替卡韦的环糊精包合物及其制备方法和药物应用
WO2011045646A1 (en) * 2009-10-13 2011-04-21 Council Of Scientific & Industrial Research Imidazothiazole-chalcone derivatives as potential anticancer agents and process for the preparation thereof
CN102000080A (zh) * 2010-09-21 2011-04-06 江苏先声药物研究有限公司 一种喜树碱类化合物的增溶方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074884A1 (en) * 2007-06-18 2009-03-19 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities

Also Published As

Publication number Publication date
US20170258783A1 (en) 2017-09-14
ES2629932T3 (es) 2017-08-16
IN2014DN08886A (enExample) 2015-05-22
EP2831047B1 (en) 2017-05-03
CN106074368A (zh) 2016-11-09
WO2013148228A1 (en) 2013-10-03
EP2831047A4 (en) 2015-09-02
JP2015512398A (ja) 2015-04-27
CN104520274B (zh) 2016-08-24
US9649305B2 (en) 2017-05-16
US20150064175A1 (en) 2015-03-05
CA2868787A1 (en) 2013-10-03
CN106074368B (zh) 2019-01-22
CN104520274A (zh) 2015-04-15
JP6075903B2 (ja) 2017-02-08
EP2831047A1 (en) 2015-02-04
US10010542B2 (en) 2018-07-03
AU2013240340A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
US10010542B2 (en) PFKFB3 inhibit and methods of use as an anti-cancer therapeutic
US9403769B2 (en) Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics
KR102255753B1 (ko) 뮤신 관련 질환의 치료
KR20190130023A (ko) 혈액 장애를 치료하기 위한 화합물 및 조성물
MXPA05005150A (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular.
CN105461697A (zh) 喹唑啉酮类parp-1抑制剂及含有它们的组合物和抗肿瘤用途
US12485114B2 (en) Materials and methods useful to induce cancer cell death via methuosis or autophagy or a combination thereof
WO2007062413A2 (en) Use of parp-1 inhibitors
CN102341393A (zh) 制备(+)-1，4-二氢-7-[(3s，4s)-3-甲氧基-4-甲氨基-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1，8-萘啶-3-羧酸的方法
WO2017198194A1 (zh) 一种硼酸和硼酸酯类化合物及其应用
WO2024008044A1 (zh) 大环拟肽类蛋白酶抑制剂及其用途
CN112759603B (zh) 鬼臼毒素衍生物及其应用
JP2008179567A (ja) ピラジン誘導体を有効成分とする抗がん剤
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
JP2024521824A (ja) マクロライド化合物
JP2022542697A (ja) 癌治療用ジヌクレオチド化合物及びその医薬用途
US20250152555A1 (en) Pharmaceutical Composition for Preventing or Treating Triple-Negative Breast Cancer
US20260034115A1 (en) Yap1 inhibitors
JP5370957B2 (ja) アポトーシス抑制剤
ES3044861T3 (en) Agent targeting double-membrane organelle dna
KR20080014017A (ko) (5ｚ)-5-(6-퀴녹살리닐메틸리덴)-2-[(2,6-디클로로페닐)아미노]-1,3-티아졸-4(5ｈ)-온
CN106674245A (zh) 吡喃葡萄糖基衍生物的制备及医药上的应用
CN115466264A (zh) 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
HK1120406A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired